Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Applauding the members of the public who donate their valuable experience and insight to NICE.
NICE is making changes to simplify our offer to the life sciences industry.
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
Page 6 of 10